Browse CTDSPL

Summary
SymbolCTDSPL
NameCTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like
Aliases HYA22; PSR1; RBSP3; small CTD phosphatase 3; HYA22 protein; RB protein serine phosphatase from chromosome 3; ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF03031 NLI interacting factor-like phosphatase
Function

Recruited by REST to neuronal genes that contain RE-1 elements, leading to neuronal gene silencing in non-neuronal cells (By similarity). Preferentially catalyzes the dephosphorylation of 'Ser-5' within the tandem 7 residue repeats in the C-terminal domain (CTD) of the largest RNA polymerase II subunit POLR2A. Negatively regulates RNA polymerase II transcription, possibly by controlling the transition from initiation/capping to processive transcript elongation.

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0001933 negative regulation of protein phosphorylation
GO:0006470 protein dephosphorylation
GO:0007346 regulation of mitotic cell cycle
GO:0010948 negative regulation of cell cycle process
GO:0016311 dephosphorylation
GO:0042326 negative regulation of phosphorylation
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045786 negative regulation of cell cycle
GO:0045930 negative regulation of mitotic cell cycle
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
Molecular Function GO:0004721 phosphoprotein phosphatase activity
GO:0016791 phosphatase activity
GO:0042578 phosphoric ester hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolCTDSPL
NameCTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like
Aliases HYA22; PSR1; RBSP3; small CTD phosphatase 3; HYA22 protein; RB protein serine phosphatase from chromosome 3; ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CTDSPL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCTDSPL
NameCTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like
Aliases HYA22; PSR1; RBSP3; small CTD phosphatase 3; HYA22 protein; RB protein serine phosphatase from chromosome 3; ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CTDSPL in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCTDSPL
NameCTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like
Aliases HYA22; PSR1; RBSP3; small CTD phosphatase 3; HYA22 protein; RB protein serine phosphatase from chromosome 3; ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CTDSPL in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.7110.0305
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.0360.607
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4770.743
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2150.564
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.030.985
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4510.824
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4970.245
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2360.893
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7920.683
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.6640.578
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0320.984
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1620.077
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CTDSPL in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCTDSPL
NameCTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like
Aliases HYA22; PSR1; RBSP3; small CTD phosphatase 3; HYA22 protein; RB protein serine phosphatase from chromosome 3; ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CTDSPL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCTDSPL
NameCTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like
Aliases HYA22; PSR1; RBSP3; small CTD phosphatase 3; HYA22 protein; RB protein serine phosphatase from chromosome 3; ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CTDSPL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CTDSPL.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCTDSPL
NameCTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like
Aliases HYA22; PSR1; RBSP3; small CTD phosphatase 3; HYA22 protein; RB protein serine phosphatase from chromosome 3; ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CTDSPL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCTDSPL
NameCTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like
Aliases HYA22; PSR1; RBSP3; small CTD phosphatase 3; HYA22 protein; RB protein serine phosphatase from chromosome 3; ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CTDSPL expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCTDSPL
NameCTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like
Aliases HYA22; PSR1; RBSP3; small CTD phosphatase 3; HYA22 protein; RB protein serine phosphatase from chromosome 3; ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CTDSPL and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCTDSPL
NameCTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like
Aliases HYA22; PSR1; RBSP3; small CTD phosphatase 3; HYA22 protein; RB protein serine phosphatase from chromosome 3; ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CTDSPL collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.